Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML

Blood

Volumn 129, Issue 12, 2017, Pages 1636-1645

  Löwenberg, Bob ^a   Pabst, Thomas ^b   Maertens, Johan ^c   Van Norden, Yvette ^d   Biemond, Bart J ^e   Schouten, Harry C ^f   Spertini, Olivier ^g   Vellenga, Edo ^h   Graux, Carlos ⁱ   Havelange, Violaine ^j   De Greef, Georgine E ^a   De Weerdt, Okke ^k   Legdeur, Marie Cecile J C ^l   Kuball, Juergen ^m   Van Marwijk Kooy, Marinus ⁿ   Gjertsen, Bjorn T ^o   Jongen Lavrencic, Mojca ^a   Van De Loosdrecht, Arjan A ^p   Van Lammeren Venema, Daniëlle ^q   Hodossy, Beata ^r   Breems, Dimitri A ^s   Chalandon, Yves ^t   Passweg, Jakob ^u   Valk, Peter J M ^a   Manz, Markus G ^v   Ossenkoppele, Gert J ^p   more..

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d ERASMUS MC CANCER INSTITUTE   (Netherlands)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

^f MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^g LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^h UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

ⁱ UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

^j CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^k ST ANTONIUS HOSPITAL   (Netherlands)

^l MEDISCH SPECTRUM TWENTE   (Netherlands)

^m UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

ⁿ ISALA HOSPITAL   (Netherlands)

^o HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^p VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^q HAGA HOSPITAL   (Netherlands)

^r Centre Hospitalier Regional de La Citadelle   (Belgium)

^s ZiekenhuisNetwerk Antwerpen   (Belgium)

^t GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^u UNIVERSITY HOSPITAL BASEL   (Switzerland)

^v UNIVERSITY HOSPITAL ZURICH   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; BUSULFAN; CLOFARABINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; IDARUBICIN; MITOXANTRONE; ADENINE NUCLEOTIDE; ANTINEOPLASTIC ANTIMETABOLITE; ARABINONUCLEOSIDE;

ACUTE MYELOID LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLEEDING; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CONSOLIDATION CHEMOTHERAPY; CONTROLLED STUDY; DEATH; DRUG EFFICACY; DRUG SAFETY; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; GENOTYPE; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION RATE; INTERMEDIATE RISK PATIENT; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; OPEN STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; REMISSION; WHOLE BODY RADIATION; WILD TYPE; YOUNG ADULT; ADOLESCENT; INDUCTION CHEMOTHERAPY; MORTALITY; PROCEDURES; RISK; SURVIVAL RATE;

ADENINE NUCLEOTIDES; ADOLESCENT; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ARABINONUCLEOSIDES; CLOFARABINE; CONSOLIDATION CHEMOTHERAPY; HUMANS; INDUCTION CHEMOTHERAPY; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; REMISSION INDUCTION; RISK; SURVIVAL RATE; YOUNG ADULT;

EID: 85016270969     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-10-740613     Document Type: Article

References (17)

1. Kantarjian H, Gandhi V, Cortes J, et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood. 2003;102(7): 2379-2386.
2. Burnett AK, Russell NH, Hunter AE, et al; UK National Cancer Research Institute AML Working Group. Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival. Blood. 2013;122(8): 1384-1394.
3. Faderl S, Gandhi V, O'Brien S, et al. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood. 2005;105(3): 940-947.
4. Faderl S, Wetzler M, Rizzieri D, et al. Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: Results from the CLASSIC I Trial. J Clin Oncol. 2012;30(20): 2492-2499.
5. Nazha A, Kantarjian H, Ravandi F, et al. Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients #60 years with newly diagnosed acute myeloid leukemia. Am J Hematol. 2013;88(11): 961-966.
6. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6): 2079-2088.
7. L öwenberg B, van Putten W, Theobald M, et al; Dutch-Belgian Hemato-Oncology Cooperative Group; Swiss Group for Clinical Cancer Research. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med. 2003;349(8): 743-752.
8. Löwenberg B, Pabst T, Vellenga E, et al; Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group. Cytarabine dose for acute myeloid leukemia. N Engl J Med. 2011;364(11): 1027-1036.
9. Vellenga E, van Putten W, Ossenkoppele GJ, et al; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON); Swiss Group for Clinical Cancer Research Collaborative Group (SAKK). Autologous peripheral blood stem cell transplantation for acute myeloid leukemia. Blood. 2011;118(23): 6037-6042.
10. Cornelissen JJ, Versluis J, Passweg JR, et al; HOVON; SAKK Leukemia Groups. Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 years. Leukemia. 2015;29(5): 1041-1050.
11. Cheson BD, Bennett JM, Kopecky KJ, et al; International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003; 21(24): 4642-4649.
12. Döhner H, Estey EH, Amadori S, et al; European LeukemiaNet. Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3): 453-474.
13. Breems DA, Van Putten WL, De Greef GE, et al. Monosomal karyotype in acute myeloid leukemia: A better indicator of poor prognosis than a complex karyotype. J Clin Oncol. 2008;26(29): 4791-4797.
14. Burnett AK, Hills RK, Milligan D, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: Results of the MRC AML15 trial. J Clin Oncol. 2011;29(4): 369-377.
15. Burnett AK, Russell NH, Hills RK, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol. 2012; 30(32): 3924-3931.
16. Castaigne S, Pautas C, Terr é C, et al; Acute Leukemia French Association. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): A randomised, openlabel, phase 3 study. Lancet. 2012;379(9825): 1508-1516.
17. Estey E, Levine RL, Löwenberg B. Current challenges in clinical development of "targeted therapies": The case of acute myeloid leukemia. Blood. 2015;125(16): 2461-2466.